News

Latest News:

mc2_news-image-icon-07

MC2 Biotek successfully completes plaque psoriasis study

POSTED: May 1, 2015

MC2 Biotek has received positive results from a plaque psoriasis study comparing MC2-01 PAD™ Cream (fixed dose combination of Betamethasone dipropionate/calcipotriene) to vehicle, monads, Taclonex Ointment and Taclonex Topical Suspension.

Data ...

READ FULL ARTICLE >

Events:

February 28th - 29th, 2024

MC2 Therapeutics to present at the 17th Annual European Life Sciences CEO Forum

READ MORE >

November 14th - 16th, 2023

Meet MC2 at Jefferies London Healthcare Conference

READ MORE >

May 15th - 16th, 2023

MC2 Therapeutics to present at Bio€quity Europe 2023

READ MORE >

February 7th, 2023

MC2 Therapeutics to present at the BIO CEO & Investor Conference in NYC

READ MORE >

January 9th - 12th, 2023

J.P. Morgan Healthcare Conference 2023 (San Francisco)

READ MORE >

January 8th, 2023

MC2 Therapeutics to present at the Dermatology Summit 2023 in San Francisco

READ MORE >

December 7th, 2022

MC2 Therapeutics to present at Carnegie’s Next Generation Nordic Life Science Champions Seminar 2022

READ MORE >

November 15th - 17th, 2022

MC2 Therapeutics attends the Jefferies London Healthcare Conference

READ MORE >

February 28th, 2022

MC2 exposure at PCMA Business Forum 2022

READ MORE >

August 11th, 2021

MC2 Therapeutics is proud to support National Psoriasis Action Month

READ MORE >

July 23, 2021

MC2 Therapeutics supports World Sjögren’s Day

READ MORE >